Novo Nordisk shares rise after dropping Metsera bid

Core Viewpoint - Shares in Novo Nordisk increased following the company's decision to withdraw its bid for Metsera, a U.S. weight loss drug company, thus concluding a bidding war with Pfizer [1] Group 1: Company Actions - Novo Nordisk has dropped its bid for Metsera, ending the competitive acquisition process with Pfizer [1] - The decision to withdraw from the bidding process has positively impacted Novo Nordisk's stock performance [1] Group 2: Market Reaction - The early trading session saw a rise in Novo Nordisk's shares after the announcement of the withdrawal from the Metsera bid [1]